Key result
Large heart failure cohort reveals baseline prescription rates exceeding ~80% for beta-blockers and ACEi/ARB/ARNI.
Why the study?
Prior models predicting GDMT non-adherence in heart failure have been limited by data availability, hindering providers from identifying patients who could benefit from adherence interventions.
Cohort (n=39,963)
No
Answers are grounded in this paper and cite their sources.
This large real-world HF cohort enables longitudinal adherence research; leaves open questions on optimization and outcomes.
PURPOSE: Clinic-based or community-based interventions can improve adherence to guideline-directed medication therapies (GDMTs) among patients with heart failure (HF). However, opportunities for such interventions are frequently missed, as providers may be unable to recognise risk patterns for medication non-adherence. Machine learning algorithms can help in identifying patients with high likelihood of non-adherence. While a number of multilevel factors influence adherence, prior models predicting non-adherence have been limited by data availability. We have established an electronic health record (EHR)-based cohort with comprehensive data elements from multiple sources to improve on existing models. We linked EHR data with pharmacy refill data for real-time incorporation of prescription fills and with social determinants data to incorporate neighbourhood factors. PARTICIPANTS: Patients seen at a large health system in New York City (NYC), who were >18 years old with diagnosis of HF or reduced ejection fraction (<40%) since 2017, had at least one clinical encounter between 1 April 2021 and 31 October 2022 and active prescriptions for any of the four GDMTs (beta-blocker, ACEi/angiotensin receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonist (MRA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i)) during the study period. Patients with non-geocodable address or outside the continental USA were excluded. FINDINGS TO DATE: Among 39 963 patients in the cohort, the average age was 73±14 years old, 44% were female and 48% were current/former smokers. The common comorbid conditions were hypertension (77%), cardiac arrhythmias (56%), obesity (33%) and valvular disease (33%). During the study period, 33 606 (84%) patients had an active prescription of beta blocker, 32 626 (82%) had ACEi/ARB/ARNI, 11 611 (29%) MRA and 7472 (19%) SGLT2i. Ninety-nine per cent were from urban metropolitan areas. FUTURE PLANS: We will use the established cohort to develop a machine learning model to predict medication adherence, and to support ancillary studies assessing associates of adherence. For external validation, we will include data from an additional hospital system in NYC.
No takes yet. Share an insight, caveat, or question.
Adhikari et al. (2023) conducted a cohort in Heart failure (n=39,963). Guideline-directed medication therapies (GDMTs) was evaluated. A large EHR-based cohort of 39,963 heart failure patients was established to assess medication adherence, revealing baseline prescription rates of 84% for beta-blockers and 82% for ACEi/ARB/ARNI.
Synapse has enriched 10 related papers. Consider them for comparative context: